Palomar Labs Spins Out Ariadne Bio to Advance Non-Hallucinogenic Therapy for Parkinson’s Apathy

Backed by preclinical data and funding from The Michael J. Fox Foundation, Ariadne Bio is advancing AB-300, a serotonin 2A receptor agonist, as a potential treatment for Parkinson’s-related apathy.

The post Palomar Labs Spins Out Ariadne Bio to Advance Non-Hallucinogenic Therapy for Parkinson’s Apathy appeared first on GEN - Genetic Engineering and Biotechnology News.